Showing 461 - 480 results of 1,447 for search '"liver disease"', query time: 0.07s Refine Results
  1. 461
  2. 462
  3. 463
  4. 464

    Identification of retinol dehydrogenase 10 as a shared biomarker for metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus by Fangyu Li, Rui Li, Hongjun Deng

    Published 2025-01-01
    “…BackgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is an independent risk factor for type 2 diabetes mellitus (T2DM), and its early identification and intervention offer opportunities for reversing diabetes mellitus.MethodsIn this study, we identified biomarkers for the MASLD dataset (GSE33814, GSE48452) and the T2DM dataset (GSE76895 and GSE89120) by bioinformatics analysis. …”
    Get full text
    Article
  5. 465

    Relationship between Serum Cytokeratin-18, Control Attenuation Parameter, NAFLD Fibrosis Score, and Liver Steatosis in Nonalcoholic Fatty Liver Disease by Sumitro Kosasih, Wong Zhi Qin, Rafiz Abdul Rani, Nazefah Abd Hamid, Ngiu Chai Soon, Shamsul Azhar Shah, Yazmin Yaakob, Raja Affendi Raja Ali

    Published 2018-01-01
    “…The aim of this study was to appraise the relationship between serum fragmented cytokeratin-18(CK-18), controlled attenuation parameter (CAP), and liver steatosis assessed by ultrasound (US) in nonalcoholic fatty liver disease (NAFLD) patients. Methods. Patients who underwent abdominal US were recruited, followed with measurement of CAP using Fibroscan® and serum fragmented CK-18 using enzyme-linked immunosorbent assay. …”
    Get full text
    Article
  6. 466

    A Network-Based Approach to Explore the Mechanism and Bioactive Compounds of Erzhi Pill against Metabolic Dysfunction-Associated Fatty Liver Disease by Shaojie Huang, Fei Mu, Fei Li, Wenjun Wang, Haixia Chen, Lu Lei, Yang Ma, Yi Ding, Jingwen Wang

    Published 2020-01-01
    “…Erzhi pill (EZP), a classical traditional Chinese medicine prescription, exerts a potent hepatoprotective effect against metabolic dysfunction-associated fatty liver disease (MAFLD), previously known as nonalcoholic fatty liver disease (NAFLD). …”
    Get full text
    Article
  7. 467
  8. 468
  9. 469

    PLEYOTROPIC EFFECTS OF METFORMIN by L. Ju. Morgunov

    Published 2015-01-01
    Subjects: “…nonalcoholic fatty liver disease…”
    Get full text
    Article
  10. 470
  11. 471
  12. 472
  13. 473

    Assessing the diagnostic accuracy of radiological and histological findings in the diagnosis of non-alcoholic fatty liver disease stages among patients in a tertiary hospital by Ekpe Edemekong L, Emanghe U, Ekpe EL, Obiora IC, Yemiode Itam, Akinmola OO

    Published 2024-07-01
    “…Aim and Objectives: To evaluate the diagnostic strength of ultrasound in the diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD) stages. Material and Methods: Participants were recruited from patients with fatty liver who underwent liver biopsy and baseline ultrasound at the University of Calabar Teaching Hospital between January 2023 and December 2023. …”
    Get full text
    Article
  14. 474

    The Counteracting Effect of Chrysin on Dietary Fructose-Induced Metabolic-Associated Fatty Liver Disease (MAFLD) in Rats with a Focus on Glucose and Lipid Metabolism by Gabriela Campanher, Nelson Andrade, Joanne Lopes, Cláudia Silva, Maria João Pena, Ilda Rodrigues, Fátima Martel

    Published 2025-01-01
    “…We explored the effect of chrysin, a dietary polyphenol, on hepatic lipid and glycogen accumulation, metabolic dysfunction-associated fatty liver disease (MAFLD) activity score and oxidative stress and on hepatic and adipose tissue metabolism in rats presenting metabolic syndrome-associated conditions. …”
    Get full text
    Article
  15. 475
  16. 476
  17. 477
  18. 478
  19. 479
  20. 480